A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma

LESSONS LEARNED: Our results highlight additional toxicities of dual PI3K/mTOR inhibition in the clinical setting that were unforeseen from preclinical models. Because of toxicity and lack of efficacy, BEZ235 should not be further developed in the current formulation for patients with renal cell car...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncologist
Huvudupphovsmän: Carlo, Maria I., Molina, Ana M., Lakhman, Yulia, Patil, Sujata, Woo, Kaitlin, DeLuca, John, Lee, Chung-Han, Hsieh, James J., Feldman, Darren R., Motzer, Robert J., H. Voss, Martin
Materialtyp: Artigo
Språk:Inglês
Publicerad: AlphaMed Press 2016
Ämnen:
Clinical Trial Results
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4943396/
https://ncbi.nlm.nih.gov/pubmed/27286790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0145
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk